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The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients
with resected pancreatic cancer was determined. Patients with resected adenocarcinoma of the pancreas were treated with
intravenous gemcitabine administered twice-weekly (40mgm
 2) for 5 weeks concurrent with upper abdominal radiation (50.4Gy in
51
2 weeks). At the completion of the chemoradiation, patients without disease progression were given gemcitabine (1000mgm
 2)
weekly for two cycles. Each cycle consisted of 3 weeks of treatment followed by 1 week without treatment. Forty-seven patients
were entered, 46 of whom are included in this analysis. Characteristics: median age 61 years (range 35–79); 24 females (58%); 73%
stage T3/T4; and 70% lymph node positive. Grade III/IV gastrointestinal or haematologic toxicities were infrequent. The median
survival was 18.3 months, while the median time to disease recurrence was 10.3 months. Twenty-four percent of patients were alive
at 3 years. Only six of 34 patients with progression experienced local regional relapse as a component of the first site of failure. These
results confirm the feasibility of delivering adjuvant concurrent gemcitabine and radiation to the upper abdomen. This strategy
produced good local regional tumour control.
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Cure with surgery alone for patients with operable pancreatic
adenocarcinoma remains infrequent. A small randomised trial
reported by the Gastrointestinal Study Group (GITSG) demon-
strated an improvement in median and overall survival for patients
treated with a surgical resection who were randomised to adjuvant
5-fluorouracil-based chemoradiation (vs observation) (1987). The
chemoradiation consisted of bolus 5-fluorouracil (5-FU) and split
course radiation to a total dose of 40Gy. The median and 2-year
survival for the surgery alone patients was 11 months and 18%
vs 20 months and 43%, respectively, for the patients receiving
adjuvant therapy. The European Organization for the Research and
Treatment of Cancer (EORTC) attempted to replicate the results of
the GITSG trial but failed to confirm a statistical benefit, despite a
4.5-month improvement in median survival for patients receiving
adjuvant chemoradiation (Klinkenbijl et al, 1999). In an update
of the European Study for Pancreatic Cancer (ESPAC 1) trial, six
cycles of adjuvant 5-FU chemotherapy given alone or following
split-course 5-FU-based chemoradiation appeared to provide a
survival benefit over surgery alone (Neoptolemos et al, 2004).
While the results of the ESPAC trial leave in question the role of
radiation therapy in this setting, the use of chemoradiation reflects
an accepted standard in the United States.
Gemcitabine is active as a single agent in the treatment of
pancreatic cancer (Casper et al, 1994; Carmichael et al, 1996;
Burris et al, 1997) with established radiation sensitising properties
(Shewach and Lawrence, 1995, 1996; Lawrence et al, 1996, 1997,
1999; Joschko et al, 1997; Blackstock et al, 2001). While the
vast majority of the reported phase I–III clinical trials have
utilised gemcitabine as a single agent given weekly in a single
dose, there are preclinical, pharmacologic and clinical data
suggesting gemcitabine possesses equal, if not greater, cytotoxicity
if given at a lower dose over a longer infusion time (Gandhi and
Plunkett, 1990; Grunewald et al, 1991; Boven et al, 1993; Shewach
et al, 1994).
Animal studies from the University of Michigan and MD
Anderson Cancer Center suggest that maximum radiation
sensitisation with gemcitabine is achieved with a lower dose
administered twice-weekly (Mason et al, 1999; Fields et al, 2000).
Fields et al treated squamous cell carcinoma VII xenografts with
ionising radiation combined with isotoxic drug/radiation regimens
(gemcitabine 800mgkg
 1 once weekly or 100mgkg
 1 twice-
weekly). At 28 days post-treatment, tumours treated with twice-
weekly gemcitabine and radiation were significantly smaller than
tumours treated with the once weekly schedule (Po0.03). Related
supporting clinical data come from Eisbruch et al (2001). Twenty-
nine patients with unresectable head and neck cancer received a
course of radiation concurrent with weekly infusions of low-dose
gemcitabine. Tumour biopsies were obtained after the first gemci-
tabine infusion (before radiation started), and the intracellular
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sconcentrations of dFdCTP, the active metabolite of gemcitabine,
were determined. Tumour dFdCTP levels and response rates were
similar at all dose levels (50–300mgm
 2), demonstrating that
significant tumour and normal tissue radiosensitisation can be
achieved with ‘low-dose’ gemcitabine strategies.
Several phase I/II trials combining upper abdominal radiation
and lower dose (40–90mgm
 2) twice-weekly gemcitabine have
been reported, with each suggesting that this combination is safe
and active (Blackstock et al, 1999; Pipas et al, 2001; Yavuz et al,
2001; Martenson et al, 2003). In a preoperative trial in pancreatic
cancer from Joensuu et al (2004), the investigators observed a
median survival of 25 months for patients taken to resection after
receiving preoperative twice-weekly gemcitabine and radiation.
While survival in the Cancer and Leukemia Group B (CALGB) trial
of twice-weekly gemcitabine and radiation for locally advanced
unresectable patients was only comparable to that expected with
5-FU-based chemoradiation, the regimen possessed moderate
but acceptable toxicity and local control appeared improved
(Blackstock et al, 2004).
This study was initiated to evaluate the combination of adjuvant
radiation with concurrent twice-weekly gemcitabine followed by
gemcitabine for patients with resected pancreatic cancer.
PATIENTS AND METHODS
Patient population
Patient’s age X18 years with nonmetastatic surgically resected
adenocarcinoma of the pancreas by pancreaticoduodenectomy
(Whipple procedure or total pancreatectomy) were eligible. While
patients with resected nodal disease were eligible, patients with
focally positive (microscopically) margins (tumour at the margin)
or patient’s X8 weeks from surgery were ineligible. Inclusion
criteria were the following: Eastern Cooperative Oncology Group
performance status (PS) 0–2; adequate bone marrow – ANC
(absolute neutrophil count) X1500 cellsmm
 3, platelet count
X100000 cellsmm
 3, and haemoglobin X10gdl
 1; kidney func-
tion (serum creatinine o2.0mgdl
 1) and liver function (serum
total bilirubin o2mgdl
 1). Only patients able to maintain
adequate oral nutrition and document a stable weight (no more
than 5lbs weight loss) for at least 2 weeks prior to enrollment were
eligible. Patients with prior malignancy were ineligible for the
study with the exception of those who had nonmelanoma skin
cancer, in situ cancer of the cervix, or other cancer for which the
patient had been disease free for X5 years.
All patients provided written informed consent according to
federal and institutional guidelines. Institutional review board
approvals were obtained at all participating sites.
Treatment and evaluation
A complete course of therapy was defined as a total of 18 weeks or
three cycles. Cycle 1 (weeks 1–6) incorporated the chemoradiation
portion of the trial. Gemcitabine was delivered intravenously at a
dose of 40mgm
 2 over 30min, twice-weekly on either Monday
and Thursday or Tuesday and Friday 30min prior to the radiation
therapy. During the concurrent chemoradiation, the gemcitabine
was held for 1 week if the ANC was o1500ml
 1 or the platelets
were o100000mm
 3 at the scheduled Monday dosing (the
radiation continued). If the ANC or platelets had not recovered
after the 1 week break, the gemcitabine and radiation were held
until the ANC or platelets recovered and then restarted (no
gemcitabine dose reductions). Gemcitabine doses held due to
toxicity were not made up. Preoperative CT scans of the abdomen
and surgical clips placed at the time of surgery were used to
delineate treatment volumes. An initial 45Gy was delivered to the
tumour bed and peripancreatic nodal regions plus a 1.0–2.0cm
margin. The celiac axis was treated at the discretion of the
radiation oncologist. The boost volume included the original
tumour bed volume with a 2.0cm margin. This volume received an
additional 5.4Gy. The specific design and configuration of the
fields were individualised based upon the volume and location of
the disease. Four field beam arrangements and 10–15mV photon
energies were required. In general, a four-field approach utilised
anterior–posterior and left and right lateral beams. The spinal
cord dose was limited to 45Gy. In order to decrease hepatic
irradiation, the anterior–posterior (AP/PA) fields were generally
weighted more heavily than the laterals.
During cycles 2–3, gemcitabine was administered intravenously
at a dose of 1000mgm
 2 over 30min weekly for 3 weeks followed
by 1 week of rest  2 cycles. Within a cycle, if the ANC was
between 500 and 999ml
 1or the platelet count was between 50000
and 99999mm
 3 on the day of treatment, the dose of gemcitabine
was reduced by 25%. The dose was held for an ANC less than
500ml
 1 or a platelet count less than 50000mm
 3. Patients
with nonhaematologic toxicities grades 0–2 (and grade 3 nausea/
vomiting) received full-dose gemcitabine. For grade 3 nonhaema-
tologic toxicities other than nausea/vomiting, patients received
either 75% of the gemcitabine dose or no treatment at the
discretion of the treating physician. The gemcitabine dose was
held for grade 4 nonhaematologic toxicities and missed doses were
not made up.
Patients were evaluated for disease progression clinically and
radiographically every 2 months the first year and then every 3
months. Weekly complete blood cell counts were required during
treatment and the use of growth factors was discouraged. Disease
progression was defined as the appearance of any new lesions on
radiographic studies or in patients experiencing complications
consistent with local–regional progression of disease, including
new gastric outlet obstruction, duodenal obstruction, new bile duct
obstruction, a decline in PS of at least one level, or the
development of ascites not associated with gemcitabine therapy.
Statistical considerations
The statistical analysis was performed at the Wake Forest
University Comprehensive Cancer Center. The principal outcome
measure used to quantify treatment effect was the Kaplan–Meier
estimated 1-year survival. A two-stage phase II design was planned
to test the null hypothesis that 1-year survival was p35% vs the
alternative hypothesis that 1-year survival was X50% with type I
and II errors of 10%. The study was originally designed to accrue a
maximum of 82 patients with an interim analysis after 53 patients.
As the accrual was slower than expected, the study was closed with
a sample size of 47 patients that provided an 78% power for testing
the study hypothesis. The Kaplan–Meier method was also used to
estimate the progression-free survival distribution. Overall survi-
val was measured from the date of study entry until death due to
any cause. Recurrence-free survival was measured from the date of
study entry until disease progression or death from any cause. The
log-rank test was used to assess differences in time-to-event
distributions between patient subgroups.
Patient registration and data collection were managed by
the Wake Forest University Statistical Center (US) and Centre
Hospitalier Lyon Sud (France). Data quality was ensured by careful
review of all data by the Wake Forest University Statistical Center,
the Centre Hospitalier Lyon Sud staff and the study chairpersons.
RESULTS
Patient characteristics
Between June of 1999 and October of 2003, 47 patients with
resected pancreatic cancer were entered onto this multicenter trial.
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sThis analysis incorporates data available from 46 patients,
excluding one patient who was entered but was subsequently
deemed ineligible (median follow-up 38.6 months). The pretreat-
ment characteristics of the patients entered onto this trial are listed
in Table 1. The median age was 61 years (range 35–79 years),
all patients were resection margin negative and the median
number of lymph nodes evaluated was 7 (range 1–27). The
majority of patients (470%) were lymph node positive and had
advanced T-stage disease.
Toxicity
Table 2 shows the grade 3 and 4 toxicities. Grade 3 and grade 4
haematologic toxicities, primarily neutropenia, occurred in 15
and 11% of patients, respectively. Grade 3 and 4 gastrointestinal
toxicities, specifically nausea and vomiting, were uncommon,
occurring in 13% and 0% of patients respectively. There was one
death attributed to a gastrointestinal bleed that was scored as
possibly treatment related. Forty-six percent of patients completed
all 18 weeks of planned therapy while 74% of patients completed
all planned chemoradiation and received X50% of the intended
doses of maintenance chemotherapy.
Survival and patterns of failure
The median survival and progression-free survival for the entire
patient cohort were 18.3 (95% CI¼13.7, 25.9) months and 10.3
(95% CI¼9.0, 13.2) months, respectively. Sixty-nine percent (95%
CI¼0.55, 0.83) of patients were alive at 1 year and 24% were alive
at 3 years (Figure 1). T-stage was prognostic; the time to
recurrence for patients with T1–T2 disease was 16 months vs 9.2
months for patients with T3–T4 tumours (P¼0.05). Overall
median survival trended towards statistical significance as it
related to T-stage, 30.7 months for the T1–T2 patients vs 14.6 for
patients with T3–T4 tumours (P¼0.06). Neither ethnicity nor
gender was related to survival (Table 3); however, there were very
few African-American patients in this study. While patients in the
US experienced a slightly improved survival (nonstatistical), this
likely relates to the overall more advanced T-stage and nodal stage
disease found in patients enrolled in France.
At the time of this analysis, documented progression had
occurred in 34 of the 46 patients. Three other patients died of their
disease and were considered to have progressed. Distant progres-
sion represented the most frequent location of initial treat-
ment failure (Table 4). Recurrence in the liver was a component
of failure in 28 of 34 patients (82%) while six patients (18%)
developed pulmonary metastasis. Ascites indicative of peritoneal
carcinomatosis occurred in five of 34 (15%). Local–regional
recurrence was observed in six of 34 patients who progressed
(18%).
DISCUSSION
The vast majority of the reports attempting to combine upper
abdominal radiation and gemcitabine have been in the setting of
locally advanced pancreatic cancer. In several instances, the
Table 1 Patient characteristics
Characteristic No. (%)
Total 46 (100)
Age – median (range) 61 (35–79)
Country
France 21 (46)
USA 25 (54)
Performance status
ECOG 0 30 (65)
ECOG 1 15 (33)
ECOG 2 1 (2)
Sex
Male 22 (48)
Female 24 (52)
Ethnicity
Caucasian 43 (93)
African-American 3 (7)
Tumour size
X3.0cm 27 (64)
o3.0cm 15 (36)
Unknown 4 (—)
Lymph node
Negative 13 (30)
Positive 30 (70)
Unknown 3 (—)
Tumour stage
T1/T2 12 (27)
T3/T4 32 (73)
Unknown 2 ( )
Table 2 Grade III and IV toxicities experienced in 46 evaluable patients
Grade 3 Grade 4
Toxicity n( % )n( % )
Haematologic
Neutrophils/granulocytes 7 (15) 5 (11)
Anaemia 8 (17) 2 (4)
Thrombocytopenia 6 (13) 1 (2)
Constitutional
Fatigue (lethargy/malaise) 10 (22) 0 (0)
Weight loss 1 (2) 0 (0)
Gastrointestinal
Anorexia 1 (2) 1 (2)
Nausea 6 (13) 0 (0)
Dehydration 0 (0) 0 (0)
Vomiting 2 (4) 0 (0)
0 1 22 43 64 86 0
Time (months)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
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Overall survival
Recurrence−free survival
Figure 1 Overall and recurrence free survival.
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sreported toxicity has been significant. A phase II ECOG trial
evaluating radiation and concurrent protracted venous infusion
5-FU (200mgm
 2day
 1) with weekly gemcitabine (50–
100mgm
 2) was closed early due to excessive toxicity; three out
of seven patients developed severe gastrointestinal toxicities
(Talamonti et al, 2000). A phase II Cancer and Leukemia Group
B trial evaluating a similar regimen found the toxicity to be
acceptable (Mamon, personal communication). In data from MD
Anderson Cancer Center, Wolff et al (2001) observed grade III/IV
haematologic toxicity in over 50% of patients receiving weekly
gemcitabine at doses ranging from 350 to 500mgm
 2, with 44% of
the patients requiring hospital admission for severe nausea/
vomiting and dehydration. An expanded retrospective review of
patients receiving gemcitabine-based chemoradiation at MD
Anderson, as reported by Crane et al (2001), further reflects the
difficulties of combining the systemic toxicities of ‘full dose’
gemcitabine with the local–regional toxicities associated with
radiation with the substantial radiation sensitisation of gemcita-
bine to the upper abdomen. The only trial to date able to achieve
‘full dose’ gemcitabine in this setting was reported by the
University of Michigan utilising very specific radiation treatment
guidelines (McGinn et al, 2001). As reported by McGinn et al, the
treated tumour volume was restricted to the gross tumour with a
1.0cm margin. No prophylactic nodal irradiation was given and
the recommended phase II radiation dose was 36Gy delivered in
2.4Gy fractions.
The clinical experience with radiation and gemcitabine for
pancreatic cancer in the adjuvant setting is more limited.
Investigators at the University of Michigan found the strategy of
fixing the dose of gemcitabine and escalating the ‘limited field’
radiation to be well tolerated in the adjuvant setting (Allen et al,
2004). In this phase I study of 32 patients with resected pancreatic
cancer, gemcitabine at a dose of 1000mgm
 2 was given on days 1,
8 and 15 of a 28-day cycle concurrent with the radiation. The
maximum tolerated dose of radiation was 39Gy. While these are
phase I data, the median survival was an acceptable 16.5 months.
Van Laethem et al, in a feasibility study, found that gemcitabine
(300mgm
 2) given weekly with split-course radiation (40Gy/20
fractions over 6 weeks) was tolerable following three cycles of
standard dose gemcitabine (1000mgm
 2 day 1 and 8 q 21 days)
(Van Laethem et al, 2003). While limited to 22 patients, the median
disease-free survival and overall survival was 6 and 15 months,
respectively. In the present trial, 74% of patients were able to
complete the entire chemoradiation portion of the study and
receive X3 of the six planned doses of maintenance chemotherapy.
This observation, along with the modest toxicity observed,
suggests this regimen is well tolerated in the adjuvant setting.
In an attempt to put these results into perspective, Table 5
provides the results of selected phase III trials evaluating adjuvant
chemoradiation strategies. The GITSG study found a benefit with
the addition of adjuvant chemoradiation (vs observation) in a trial
of 43 patients (1987). In a randomised study from the EORTC,
which was not statistically significant, an almost 5-month survival
advantage was observed for patients with pancreatic head cancers
randomised to resection and adjuvant 5-FU-based chemoradiation
vs observation (Klinkenbijl et al, 1999).
The ESPAC-1 trial attempted to evaluate several adjuvant
strategies (Neoptolemos et al, 2004). Following resection, patients
Table 3 Overall survival (in months) by demographic characteristics
Characteristic n Median 95% CI P-value
Overall 46 18.3 13.7, 25.9
Age group 0.44
o60 22 20.5 14.5, 31.4
X60 24 14.7 9.5, 25.9
Country 0.21
France 21 17.0 7.8, 25.9
USA 25 19.4 13.7, NA
Gender 0.83
Female 24 19.4 10.9, 30.7
Male 22 18.1 14.5, 25.9
Ethnicity 0.10
African descent 3 13.7 4.4, 18.3
Non African descent 43 19.4 13.4, 26.4
Performance status 0.29
0 30 18.3 13.4, 25.9
1–2 16 16.1 10.2, NA
Tumour size 0.23
o3cm 15 16.1 10.9, 20.5
X3cm 27 19.4 13.7, 45.7
Nodal status 0.15
Negative 13 30.7 13.7, NA
Positive 30 15.4 9.7, 20.5
Stage 0.07
T1,2 12 30.7 18.3, NA
T3,4 32 14.6 10.2, 20.9
NA, not applicable
Table 4 Sites of first recurrence
Organ site
Number of
patients
% of patients with
documented progressions
Liver 28 (82)
Pancreas/regional nodes 6 (18)
Ascites (carcinomatosis) 5 (15)
Pulmonary 3 (9)
A number of patients progressed synchronously in multiple sites.
Table 5 Phase III adjuvant chemoradiation trials for adenocarcinoma of
the pancreatic head
Trial Treatment n
% Stage
XT3/
%node (+)
Median
survival
(months)
GITSG (1987) Observation 22 35/28% 10.9
40Gy+5-FU
a 21 20.0
EORTC (Klinkenbijl
et al, 1999)
Observation 60 0/47% 12.6
40Gy+5-FU
b 54 17.1
ESPAC (Neoptolemos
et al, 2004)
Observation 69 16.9
6 Cycles 5-FU 75 30/59% 21.6
40Gy+5-FU
b 73 13.9
40Gy+5-FU
c 72 19.9
*WFU/Lyon (phase II) 50Gy+
Gemcitabine
d
47 74/70% 18.3
aPatients received 5-FU (2 doses) during the radiation followed by 2 years of monthly
therapy.
bPatients received 5-FU (2 doses) during the radiation only.
cPatients
received 5-FU (2 doses) during the radiation followed by six additional months of 5-
FU therapy.
dPatients received Gemcitabine (12 doses) during the radiation followed
by two additional months of Gemcitabine. 5-FU, 5-fluorouracil.
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sreceived either no therapy (observation), split-course radiation
with 5-FU given during weeks 1 and 5 (no maintenance chemo-
therapy), six cycles of adjuvant/maintenance 5-FU chemotherapy,
or split-course radiation with 5-FU followed by six cycles of
adjuvant/maintenance 5-FU chemotherapy. The data from the
ESPAC trial are difficult to interpret as the design of the trial
allowed not only for randomisation between chemoradiation and
observation but also a separate randomisation according to
physician preference, for chemotherapy only, chemoradiation, or
observation. Of the 541 patients, 346 (63%) had undergone either
‘background’ chemotherapy or chemoradiation prior to rando-
misation. In evaluating the most clinically relevant treatment arms,
median survival for patients randomised to chemotherapy (alone)
was 21.6 vs 19.9 months for those patients receiving chemoradia-
tion followed by adjuvant/maintenance chemotherapy, suggesting
no benefit with the addition of the radiation. Unfortunately, only
62% of the chemoradiation patients actually received the
prescribed 40Gy of radiation and, as stated by the authors, most
of the protocol violations (50%) on the chemoradiation treat-
ment arms were due to the patient’s decision not to receive the
assigned treatment.
In our study, the strategy of combining radiation with
gemcitabine resulted in an acceptable median survival of over 18
months, despite the vast majority of patients having T3–T4 and/or
node positive cancers. As shown in Table 5, the EORTC trial, which
only allowed patients with T1–T2 tumours to be enrolled, achieved
a median survival of 17 months in patients with pancreatic head
cancers. While our trial only included 12 patients who would have
been eligible for the EORTC study, the median survival for those
patients was 31 months.
The results of our phase II trial may reflect an improved local–
regional control of disease as well as an improved systemic
approach. The 15% local–regional failure rate observed in the
EORTC trial in both the observation and treatment arms is likely
accurate for patients with node negative (53%) and/or T1–T2
periampullary/pancreatic head tumours. In our 46 patient trial,
18% of the patients with documented recurrences had local–
regional failures, despite T3–T4 tumours and node positive
patients accounting for 73 and 70% of the patients enrolled,
respectively. The overall local recurrence (alone) rate in the ESPAC
trial was 35% and likely reflects the anticipated local failure rate for
patients with T3–T4 and/or node positive disease.
It is also possible that the two cycles of standard dose
gemcitabine delivered following the chemoradiation may have
improved outcomes. In a study of 368 patients with resected
pancreatic cancer randomised to observation vs 6 months of
adjuvant gemcitabine chemotherapy, Neuhaus et al (2005)
observed a 14-month time to tumour recurrence for those patients
receiving gemcitabine vs 7.5 months for those receiving no
further therapy. The majority of patients in this trial had T3–T4
tumours and node positive disease. While survival results were
not presented, these data suggest that gemcitabine may
provide improved systemic disease control in the adjuvant setting.
In the previously referenced CALGB experience utilising this
strategy for patients with locally advanced unresectable disease,
survival was not improved beyond that observed with 5-FU-based
chemoradiation. However, this regimen in the adjuvant setting
may be more promising. This perhaps reflects improvements in
local–regional disease control with adjuvant gemcitabine-
based chemoradiation along with improved systemic therapy
(maintenance gemcitabine).
In conclusion, this phase II study confirms the feasibility and
acceptable overall toxicity of adjuvant gemcitabine-based chemo-
radiation followed by maintenance gemcitabine chemotherapy for
patients with resected pancreatic cancer. The time to disease
recurrence and overall median survival were acceptable while local
tumour control appeared improved.
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